Atopic Dermatitis

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Latest News

FDA stamp of approval | Image Credit: Olivier Le Moal - stock.adobe.com
FDA Approves Tapinarof Cream 1% for Patients With Atopic Dermatitis

December 16th 2024

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis.

man resting hands on top of walking cane | Image Credit: sergign - stock.adobe.com
Study Finds Increased Impaired Mobility by Sex, Age in Atopic Dermatitis

June 30th 2024

E-cigarettes | Image Credit: lezinav - stock.adobe.com
Parental e-Cigarette Use May Increase Pediatric AD Risk

May 22nd 2024

Female patient with AD | Image Credit: Prostock-studio - stock.adobe.com
Study: Visible AD Impacts Romantic Relationships, Occupation, Sexual Health of French Female Patients

May 19th 2024

Patient scratching atopic dermatitis (AD) on hand | Image Credit: Ольга Тернавская - stock.adobe.com
Patients With AD Prioritize Itch Control in Treatment Preferences

May 14th 2024

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives

More News

urban scene
December 23rd 2022

Study Examines Effect of Biologics on IgE Levels in Urban Settings

AJMC Staff
This study was prompted by recent findings that ultra-low IgE levels (IgE <2.5 kU/L) may be linked with a higher risk of cancers.
Patient with atopic dermatitis.
December 22nd 2022

Adjuvant Baricitinib, Topical Corticosteroids Show Long-term Efficacy in Moderate-to-Severe AD

Matthew Gavidia
Adult patients with moderate-to-severe atopic dermatitis (AD) in the phase 3 BREEZE-AD7 study showed sustained improvement of AD signs and symptoms after 68 weeks with combination treatment of bariticitinib and topical corticosteroids.
Eye.
December 16th 2022

Greater Risk of Cataract Surgery Shown in Patients With Atopic Dermatitis, Allergic Diseases

Matthew Gavidia
Korean patients with allergic diseases, including atopic dermatitis (AD), allergic rhinitis (AR), and asthma, had a higher risk of cataract surgery, and the combination of AD and AR resulted in the highest risk.
Child.
December 9th 2022

Childhood Maltreatment Associated With Atopic Disease

Matthew Gavidia
Patients exposed to childhood maltreatment were at greater risk for developing atopic disease compared with unexposed counterparts, and risk of atopic dermatitis and allergic rhinoconjunctivitis may have been attentuated by misdiagnosis.
Itchy skin.
December 8th 2022

New and Emerging Treatments for Atopic Dermatitis

Carrie Nagorka
Matthew Zirwas, MD, FAAD, associate professor of dermatology at Ohio University in Athens, Ohio provides updates on treatment options for AD at the 2022 SDPA Fall Conference.
Mother and baby.
December 1st 2022

Early Life Antibiotic Exposure Linked With Lower Risk of Atopic Dermatitis

Matthew Gavidia
Early life exposure to antibiotics, particularly during weeks 2, 3, and 4 of life, was associated with a decreased risk of atopic dermatitis development.
Jason Ezra Hawkes, MD, MS, FAAD.
November 24th 2022

Dr Jason Ezra Hawkes on Advances in Clinical Research and Gaps in Knowledge for Atopic Dermatitis

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on how clinical studies in atopic dermatitis (AD) are increasingly investigating topics that remain unknown for disease management, including primary vs secondary failures and AD pathophysiology across different ethnic groups.
Diversity.
November 20th 2022

High Burden of AD, Bacterial Skin Infections Seen in Young Urban-Living Indigenous People

Matthew Gavidia
Urban-living Indigenous children and young people in high-income countries reported a higher likelihood of current and severe symptoms of atopic dermatitis (AD) compared with a non-Indigenous population, as well as a higher incidence of bacterial skin infections.
Jason Ezra Hawkes, MD, MS, FAAD.
November 18th 2022

Dr Jason Ezra Hawkes: Education on Chronic Nature, Subtypes of AD Key in Managing Diverse Patients

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed why it is important for dermatologists to educate patients on atopic dermatitis (AD) and keep an open mind on variations in disease presentation by skin color.
Topical calcineurin inhibitor cream.
November 14th 2022

Topical Calcineurin Inhibitors for AD Not Associated With Cancer

Matthew Gavidia
Pimecrolimus and tacrolimus, 2 topical calcineurin inhibitors for the treatment of atopic dermatitis (AD), were not shown to increase the risk of cancer based on moderate-certainty evidence from a systematic review and meta-analysis.
Black patients and doctor.
November 10th 2022

Investigating Real-World Effectiveness of Disease-Modifying Therapies in AD by Skin Type

Matthew Gavidia
Real-world patients with atopic dermatitis with dark skin types showed greater mean reduction in disease severity between baseline and 6 months with dupilumab compared with those with light skin types, whereas no differences were observed regarding severity reduction for methotrexate and ciclosporin.
Climate change
November 4th 2022

Climate Change’s Impact on Skin Disease and Vulnerable Populations

Pearl Steinzor
More than 3 billion people worldwide live within highly vulnerable areas with implications for skin health, according to climate change policy makers.
Jason Ezra Hawkes, MD, MS, FAAD.
October 26th 2022

Dr Jason Ezra Hawkes on Prior Authorization, Clinical Documentation Issues Limiting Atopic Dermatitis Treatment Access

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed how prior authorizations and other insurance requirements are limiting treatment access in atopic dermatitis and how dermatologists can help ameliorate these approval issues.
adult person touching skin.
October 25th 2022

Dupilumab Efficacy in AD Not Affected by Age of Disease Onset

Matthew Gavidia
Dupilumab exhibited similarly significant and sustained improvements in atopic dermatitis (AD) signs, symptoms, and quality of life of adult patients with moderate to severe AD, regardless of age of disease onset, compared with placebo.
phone app.
October 17th 2022

Improved Treatment Adherence, Clinical Outcomes Associated With Digital Intervention in Atopic Dermatitis

Matthew Gavidia
A digitally delivered targeted intervention of symptom and trigger education, treatment reminders, lifestyle coaching, and healthy lifestyle support demonstrated significant improvements in treatment adherence and related clinical outcomes among Icelandic patients with atopic dermatitis.
Prolonged Corticosteroid Exposure Associated With Adverse Effects for Patients With Atopic Dermatitis
October 12th 2022

Prolonged Corticosteroid Exposure Associated With Adverse Effects for Patients With Atopic Dermatitis

Julia Bonavitacola
Patients with atopic dermatitis reported that exposure to corticosteroid treatment throughout their lifetime put them at a risk for negative outcomes.
Jason Ezra Hawkes, MD.
October 6th 2022

Dr Jason Ezra Hawkes Addresses Immunotherapy Innovation, Uptake Issues in Atopic Dermatitis

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed recent advancements in immunotherapy for atopic dermatitis and what unmet needs persist to address uptake issues and patient-specific care needs.
homes.
October 3rd 2022

Dampness and Mold at Home Linked With Greater Risk of Atopic Dermatitis, Asthma

Matthew Gavidia
Children who lived in apartments or newer buildings were also found to have an increased risk of atopic dermatitis later in life.
Adult and child holding hands.
September 26th 2022

Skin Biomarkers Found to Predict Development of Pediatric Atopic Dermatitis

Matthew Gavidia
Significant alterations were observed in lipid levels and other skin biomarkers for infants who developed atopic dermatitis (AD) vs controls, with phytosphingosine associated with the highest AD prediction accuracy.
Jason Hawkes.
September 24th 2022

Dr Jason Ezra Hawkes Discusses Clinical Considerations for Biologic Treatment in Atopic Dermatitis

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on the importance of shared decision-making in deciding which biologic would best alleviate disease burden in patients with moderate to severe atopic dermatitis.
Mother and child.
September 22nd 2022

Early Use of Short-term Emollients Linked With Reduced Incidence of AD in High-risk Infants

Matthew Gavidia
Early initiation of daily specialized emollient use until 2 months was associated with a reduced incidence of atopic dermatitis development among high-risk infants.
itch.
September 14th 2022

Ruxolitinib Cream Linked With Rapid Reduction of Itch in Atopic Dermatitis

Matthew Gavidia
Significantly more patients given ruxolitinib cream vs vehicle demonstrated rapid improvements in itch that were sustained over time.
Jason Ezra Hawkes, MD.
September 10th 2022

Dr Jason Ezra Hawkes on Diagnostic Challenges, Strategies in Atopic Dermatitis

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on diagnostic challenges for atopic dermatitis and tips for clinicians in screening for the condition.
Adult holding child hand.
September 7th 2022

Early-Onset AD May Affect Cognitive Functioning in Children

Matthew Gavidia
Pediatric patients who developed atopic dermatitis (AD) before 2 years of age had an increased risk of neurodevelopmental dysfunction, including gross and fine motor skills, at 6 years old.
Atopic dermatitis.
August 30th 2022

AD Diagnosis, JAK Inhibitor Use Not Shown to Increase Risk of Venous Thromboembolism

Matthew Gavidia
Patients with atopic dermatitis (AD) were not found to be at greater risk of venous thromboembolism, regardless of Janus kinase inhibitor use, according to this new meta-analysis.
Jason Ezra Hawkes.
August 26th 2022

Dr Jason Ezra Hawkes Discusses How AD Immunology Informs Screening Practices

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, explained the utility of type 2 inflammation pathways and the microbiome in understanding the immune dysregulation associated with atopic dermatitis (AD).
Food.
August 23rd 2022

Benefits of Dietary Elimination May Not Outweigh Risks in Atopic Dermatitis

Matthew Gavidia
Findings of a meta-analysis show that use of dietary elimination had a minimal effect on the severity of atopic dermatitis and may increase the risk of developing immunoglobulin E–mediated food allergy.
biologic.
August 18th 2022

Drug Survival of Dupilumab Affected by Immunosuppressive Therapy, Older Age in AD

Matthew Gavidia
Investigator Global Assessment score of very severe atopic dermatitis (AD) was associated with dupilumab discontinuation due to adverse effects, although generally adequate 1-, 2-, and 3-year drug survival rates were also observed.
Depression.
August 10th 2022

Race, Insurance Type Among Predictors of Depressive Symptoms in Atopic Dermatitis

Matthew Gavidia
Most patients with atopic dermatitis had flunctuating levels of depressive symptoms, with having public or no insurance, more severe itch, and skin pain cited as additional predictors of adverse mental health outcomes.
patient and physician.
August 8th 2022

Investigating Patient Preferences for Atopic Dermatitis Treatment

Matthew Gavidia
European adult patients with atopic dermatitis most valued therapies that had rapid onset, oral administration, and were able to be paused—even at the expense of reduced efficacy.
<12345678>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo